GlassScriptPhysician profile
Adam Wayne Medlin
NPI 1538517602
$66,529.05
in general payments reported to CMS, 2019-2025
29 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,425 · 2022: $12K · 2023: $18K · 2024: $13K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $8,651 · Travel and Lodging: $4,738 · Education: $92.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,633.86 |
| Food and Beverage | $8,651.12 |
| Travel and Lodging | $4,737.80 |
| Education | $92.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,315.16 | 2021-2025 | |
| Janssen Biotech, INC. | $8,610.01 | 2021-2025 | Tremfya, Stelara, Simponi |
| Janssen Scientific Affairs, LLC | $6,610.02 | 2021-2023 | Stelara |
| Pfizer INC. | $1,758.99 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,088.08 | 2021-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $683.22 | 2021-2024 | Xifaxan |
| Celgene Corporation | $545.63 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $276.66 | 2021-2023 | Zeposia |
| Genzyme Corporation | $245.77 | 2022-2023 | |
| Daiichi Sankyo INC. | $243.64 | 2021-2023 | Injectafer |
| Sandoz INC. | $156.61 | 2024 | |
| Qol Medical, LLC | $130.22 | 2022-2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $114.83 | 2021-2023 | Linzess |
| Gilead Sciences, INC. | $109.68 | 2021-2023 | |
| Lilly USA, LLC | $91.99 | 2023-2024 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $79.50 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $73.47 | 2023 | |
| Redhill Biopharma INC. | $67.38 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Phathom Pharmaceuticals, INC. | $47.85 | 2023 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $45.52 | 2023 | Dupixent |
| Mylan Institutional INC. | $39.70 | 2023 | Hulio |
| Intercept Pharmaceuticals, INC. | $32.95 | 2021 | |
| Vivus LLC | $32.72 | 2021 | |
| Ardelyx, INC. | $29.25 | 2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $23.78 | 2021 | |
| Biocon Biologics INC | $23.20 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $17.66 | 2022 | |
| Merck Sharp & Dohme LLC | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Medlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.